Compare Teradyne, Inc. (TER) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs TG Therapeutics Inc — how do they compare? Teradyne, Inc. trades at $375.6 (market cap $52.25B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Teradyne, Inc. is far larger — about 6.3× TG Therapeutics Inc's market cap, and Teradyne, Inc. pays a 0.16% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TER | TGTX | |
|---|---|---|
Market Cap | $52.25B | $8.26B |
Sector | Technology | Health |
52-Week High | $483.84 | $59.06 |
52-Week Low | $90.15 | $26.39 |
Enterprise Value | $52.08B | $8.50B |
Dividend Yield | 0.16% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
